Compare Extra Space Storage, Inc. (EXR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Gilead Sciences, Inc. — how do they compare? Extra Space Storage, Inc. trades at $133.26 (market cap $28.12B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 6.5× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 108 Days and Gilead Sciences, Inc. for 111 Days on average.
| EXR | GILD | |
|---|---|---|
Market Cap | $28.12B | $182.40B |
Volume | 2,595,579 | 4,469,821 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $155.80 |
52-Week Low | $126.67 | $116.74 |
Typical Hold Time | 108 Days | 111 Days |
Enterprise Value | $41.84B | $205.46B |
Dividend Yield | 4.87% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $131.70, down 1.64% with a bearish technical signal. The company maintains strong fundamentals with consistent earnings beats, 27.79% net margin, and $974M net income. Revenue growth has been steady from $1.9B in 2022 to $3.4B in 2025. Analyst consensus is split with 14 Buy and 14 Hold ratings, targeting $158.33 average price. Recent leadership transition to Noah Springer as CEO effective January 2027 adds strategic focus.
EXR presents a balanced risk-reward profile with solid operational performance offset by technical weakness. The REIT's scale, 94.2% occupancy, and dividend yield support long-term value, though current price action suggests near-term pressure. Debt levels at 46.63% debt-to-asset ratio require monitoring amid rising interest rates. Upside potential exists if Q3 2026 earnings beat expectations on October 27.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
